People on the move: results season special
Amgen veteran Dennis Fenton has joined Hospira’s board of directors.
Since his retirement in 2008, Fenton has been serving as a member of the Society for Industrial Microbiology and also on the boards of Dendreon, Napo Pharmaceuticals, Genelux, Xenoport and Kythera Biopharmacals.
His appointment comes as Hospira try to up its game in the manufacturing space, according to CEO Michael Ball who said the move supports the firm's "commitment to establish manufacturing as a competitive advantage."
During the Q2 conference Call, Ball also said the firm will use the lessons learned when fixing problems at its Rocky Mount, NC, plant – flagged up by the FDA last year – to boost Hospira’s popularity in the production arena.
“We are sharing our learnings at Rocky and other facilities across the organisation to ensure implementation of best practices and to holistically put in place modern and robust quality processes and systems,” he said.
Teva Pharmaceutical has named Carlo De Notaristefani president and CEO of global operations.
Previously president of technical operations for Bristol Myers Squibb (BMS), De Notaristefani will take charge of product supply and the manufacturing network.
He joins as the firm increases focus on pulling up its once flagging US generics biz, which showed a 28 per cent increase from last year in Q2 results hitting net revenues of $2.5bn.
During a webcast with investors, CEO Jeremy Levin said he expects continued growth, and said in the results: “Overall, we continue to see tremendous opportunities ahead, and look forward to rebuilding shareholder value over time.”
The firm also hired Aharon Yaari as the executive VP of its newly created organisation, Community and Institutional Affairs, aimed at promoting social responsibility, philanthropy and academic relations.
AP Pharma announced three new board members in its second quarter results as it prepares to commercialise its lead product candidate, APF530, for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
The new members are Robert Rosen who is managing partner of Scotia Nordic, and two heads from Ardea with president and CEO Barry Quart and executive VP and COO of biosciences Stephen Davis.
In the earnings presentation, president and CEO John Whelan, said: “With the recent closing of our common stock offering, we are in a strong financial position as we approach the commercialization phase with our lead product candidate, APF530.”
Executive VP and CFO Kevin Tully has announced his intention to leave Insmed in December when his contract runs out.
He cited “family reasons” as the reason for his planned departure. The news preceeds the firm’s earnings results which will be released later this week.
"I would like to thank Kevin for his considerable contributions to Insmed in the 11 years he has spent with the company," said Timothy Whitten, Insmed's president and CEO.
